Next Phase Newsletter

Founded 2013, a venture capital firm is headquartered in San Francisco. The firm is investing from its most recent fund, which closed in early 2020 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Founded in 2017, the firm is a family office located on the West Coast and registered in the Cayman Islands. Managing $25M Angel fund, the firm invests in angel and seed stage, and its typical allocation size is between $100,000 to $250,000. The firm invests in companies based in the United States, especially in the Silicon Valley area, and normally invests four to five companies every year.

The firm is interested in diagnostics and medical devices in general, especially cancer diagnostics. Regarding therapeutics, it is open to the data platforms for therapeutics and Orphan diseases.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The fund was founded in 2019 and based on the West Coast. The firm is a sub-fund of a larger platform based in Asia, and it is managing a $10M fund dedicated to healthcare investments. The fund prefers to invest early, typically from pre-seed to series A/B. Initial investments can range from $50K to $0.5M and the firm will reserve for follow-on rounds. The fund prefers to co-invest and are looking for companies based in the US.

The fund primarily focuses on in medical devices and digital health. Examples of interested areas include digital therapeutics and remote patient monitoring. The firm is willing to consider technologies at an early stage of development as long as they have some proof of concept. The firm is interested in indications such as cardiovascular disorders, ophthalmology, dental and orthopedic.

The fund prefers management teams with strong industry ties and like to see founders in management team positions. The firm does not usually take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The firm is a single family office based in the Midwest. The firm actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.

The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.

The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A healthcare-dedicated investment firm founded in 2015 with offices in USA has 4 active investment vehicles that allow them to work with companies across various stages of development including private equity, long/short hedge fund, crossover venture fund, and SPAC.

In terms of early-stage opportunities, the firm allocates a few million dollars as initial investment (at a minimum), amount varying on a deal-by-deal basis, and is capable of investing up to $50M over the company’s lifecycle. The firm is open to North American and European opportunities.

The firm is interested in therapeutics, medical devices, tools, labs/diagnostics, and pharmaceutical services. The firm is opportunistic in terms of subsectors and will consider all things healthcare.

The firm prefers to work with management teams that have entrepreneurial experience. The business must show strong potential, and either be revenue-generating or have visibility to approach positive revenue in the next 12-24 months. The company should be built around strong and distinguishable IP that presents a significant market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical headquartered in China with more than 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.) has their main business covering chemical and biological medicines, pharmaceutical packaging, and trading.

The investment subsidiary of this pharmaceutical has 200 million RMB assets under management, and is looking for investment and in-licensing opportunities in novel drug research and development.  The firm also invests in funds. The firm’s allocation size is decided case by case.

The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. The firm is interested in distribution rights. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.

The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.

The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.